News | July 19, 2007

Bioresorbable Collagen Scaffold Treats PFO

July 20, 2007 – Oraganogenesis Inc. announced that it has received regulatory approval in Canada and Europe for BioSTAR, a device that incorporates a bioresorbable collagen scaffold used to treat patent foramen ovale (PFO), a hole in the heart that is usually asymptomatic.
BioSTAR contains FortaFlex, an innovative bioresorbable collagen scaffold that consists of highly purified and very strong sheets of collagen. FortaFlex is a modular platform technology that can be custom bioengineered to meet the needs of a variety of surgical applications using a unique lamination and crosslinking process. The BioSTAR device incorporates the FortaFlex bioresorbable collagen scaffold to function like a pair of small umbrellas. When the BioSTAR device is deployed at the PFO, an umbrella of FortaFlex sits on both the right and left atrium of the heart, effectively closing the hole between the heart chambers. Reportedly, 90-95 percent of the implant is absorbed over time and replaced with the patient’s own tissue. Micro-emboli and unfiltered blood are therefore blocked from passing into the arterial circulation and thus averting a potential stroke.

For more information: www.organogenesis.com

Related Content

Gore Cardioform ASD Occluder Receives FDA Approval
Technology | Structural Heart Occluders | June 10, 2019
W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration’s (FDA’s) premarket approval (PMA)...
Le Bonheur Children's Hospital Implants First Abbott Amplatzer Piccolo Occluder
News | Structural Heart Occluders | February 13, 2019
Le Bonheur Children's Hospital cardiologists in Memphis, Tenn., implanted the Amplatzer Piccolo Occluder, the world's...
FDA Approves Abbott's Amplatzer Piccolo Occluder
News | Structural Heart Occluders | January 16, 2019
Abbott announced the U.S. Food and Drug Administration (FDA) approved the Amplatzer Piccolo Occluder to treat patent...
FDA Approves Gore Cardioform Septal Occluder for PFO Closure Prevent Recurrent Ischemic Stroke
Technology | Structural Heart Occluders | April 03, 2018
April 3, 2018 — Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen oval
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders | February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Amplatzer PFO Occluder, St. Jude Medical, Baylor Heart and Vascular Services, Fort Worth, Texas, first patients
News | Structural Heart Occluders | February 01, 2017
Baylor Heart and Vascular Services at Fort Worth in November became the first program in Texas to implant the Amplatzer...
Overlay Init